Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with advanced hematologic malignancies, or potentially fatal blood cancers.

25 Jun 2013

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded more than $1.4 million from the National Cancer Institute of the National Institutes of Health to create a potential new drug to attack the malignant cells that cause chronic lymphocytic leukemia (CLL), which is the most common leukemia in the Western world.

20 Jun 2013

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL).

20 Jun 2013

Viewpoints: Controlling costs; Health law's guarantee of coverage; ACO liability

In the impassioned debates over healthcare, one fact is often lost-;Americans pay more but get less for their health care than residents of other high-income countries. I believe we can change that. We can improve the quality of care and reduce our expenses, saving a trillion dollars or more a year, by making our health care system more efficient (William A. Haseltine, 6/17).

19 Jun 2013

Dosimetry based on 3-D medical images estimates possible dose for targeted RIT in blood cancer patients

Outcomes can be bleak for non-Hodgkin lymphoma (NHL), a cancer that develops in the white blood cells of the immune system. Accurate estimation of radiation absorbed dose in radioimmunotherapy (RIT) based on state-of-the-art 3D imaging could lead to more personalized and effective treatments to improve patients' chances of living longer without progression of their cancer, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting.

15 Jun 2013

MRI scans of children who have undergone chemotherapy can detect early changes in their hearts

MRI scans of children who have had chemotherapy can detect early changes in their hearts finds research in biomed Central's open access journal Journal of Cardiovascular Magnetic Resonance.

10 Jun 2013

Three easy steps for cancer survivorship

Incorporating just three easy steps into a daily routine can increase a cancer patient's chance at survival, according to a physician who specializes in cancer survivorship.

31 May 2013

Cancer experts to discuss latest developments and implications of cell therapies in oncology

John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will bring together leading cancer experts, for presentation and discussion of the latest developments and implications of cell therapy and interventional immunology in oncology, on Friday, June 7 from 7:00am to 1:30pm.

23 May 2013

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Pfizer Inc. announced today the discontinuation of a Phase 3 randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma who are not candidates for intensive high-dose chemotherapy.

From Pfizer, Inc. 21 May 2013

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Cell Therapeutics, Inc. today reported that Germany's Federal Joint Committee has issued its final benefit assessment report for PIXUVRI (pixantrone), which is indicated as a monotherapy for the treatment of adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL) who have failed two or three prior lines of therapy.

20 May 2013

Imaging scans do little help to detect relapse of diffuse large B-cell lymphoma

Imaging scans following treatment for diffuse large B-cell lymphoma do little to help detect a relapse, a Mayo Clinic study has found.

17 May 2013

Annual Century for the Cure bike ride supports research on hematologic malignancies

The annual Century for the Cure bike ride that has raised more than $1 million since 2005 for research at The Cancer Institute of New Jersey is now making it possible for new scientific exploration in the area of hematologic malignancies.

14 May 2013

Researchers find a way the body can remove injured axons

Many medical issues affect nerves, from injuries in car accidents and side effects of chemotherapy to glaucoma and multiple sclerosis. The common theme in these scenarios is destruction of nerve axons, the long wires that transmit signals to other parts of the body, allowing movement, sight and sense of touch, among other vital functions.

10 May 2013

MorphoSys initiates Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia patients

Xencor announced today that MorphoSys AG has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia.

29 Apr 2013

Unavoidable damage to heart and lungs can be limited by using CVD drug

Unavoidable damage caused to the heart and lungs by radiotherapy treatment of tumours in the chest region can be limited by the administration of an ACE inhibitor, a drug commonly used in the treatment of cardiovascular disease, a group of Dutch researchers have found.

23 Apr 2013

Advances in treatment have improved the chances of survival for young patients with cancer

Over the years, advances in treatment have improved the chances of survival for young patients with cancer. But long-term survivors need to be aware of cancer treatments that may place them at increased risk of heart disease later in life.

22 Apr 2013

Shc plays key role in activating and controlling Erk

A protein which is intimately involved in cancer-promoting cell signaling also keeps a key component of the signaling pathway tied down and inactive, a team led by scientists from The University of Texas MD Anderson Cancer Center reports this week in Nature Structural Molecular Biology.

20 Apr 2013

Patients exposed to chest radiation are more likely to die after heart surgery

Patients who have open heart surgery for heart disease caused by radiation cancer treatment are nearly twice as likely to die in the years following their surgery compared to similar patients who did not undergo radiation treatment, according to new research from Cleveland Clinic published today in the American Heart Association journal Circulation.

9 Apr 2013

St. Jude Children's Research Hospital receives patent for genetically modified human immune cells for caner therapy

The United States Patent and Trademark Office today awarded St. Jude Children's Research Hospital U.S. patent number 8,399,645 for St. Jude's invention of compositions for genetically modifying human immune cells so they can destroy some of the most common forms of cancer in children and adults.

20 Mar 2013

Results from GTx's Phase 2 clinical trial of enobosarm published online

GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.

15 Mar 2013

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Infinity announces data from IPI-145 Phase 1 study in patients with advanced hematologic malignancies

TSRI scientists receive NIH grant to create new drug for chronic lymphocytic leukemia

Ibrutinib shows remarkable promise for treatment of mantle cell lymphoma

Viewpoints: Controlling costs; Health law's guarantee of coverage; ACO liability

Dosimetry based on 3-D medical images estimates possible dose for targeted RIT in blood cancer patients

MRI scans of children who have undergone chemotherapy can detect early changes in their hearts

Three easy steps for cancer survivorship

Cancer experts to discuss latest developments and implications of cell therapies in oncology

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Cell Therapeutics announces issuance of final benefit assessment report for PIXUVRI

Imaging scans do little help to detect relapse of diffuse large B-cell lymphoma

Annual Century for the Cure bike ride supports research on hematologic malignancies

Researchers find a way the body can remove injured axons

MorphoSys initiates Phase 2 clinical trial of MOR208 in B-cell acute lymphoblastic leukemia patients

Unavoidable damage to heart and lungs can be limited by using CVD drug

Advances in treatment have improved the chances of survival for young patients with cancer

Shc plays key role in activating and controlling Erk

Patients exposed to chest radiation are more likely to die after heart surgery

St. Jude Children's Research Hospital receives patent for genetically modified human immune cells for caner therapy

Results from GTx's Phase 2 clinical trial of enobosarm published online

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in